UroGen Pharma Ltd. (URGN) News
Track canonical SquawkNews coverage tagged to URGN, UroGen Pharma Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
URGN - UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
URGN - UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
EARNINGS | Aug 05, 2026, 12:00 PM UTC
L
URGN - UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
URGN - UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
EARNINGS | Jul 29, 2026, 12:00 PM UTC
L
URGN PT raised from $40 to $50, maintains Outperform @ OPCO
URGN PT raised from $40 to $50, maintains Outperform @ OPCO
EQUITY | Jul 16, 2026, 12:58 PM UTC
L
URGN - Reit Neutral, raise PT to $44 from $18 @ GSCO
URGN - Reit Neutral, raise PT to $44 from $18 @ GSCO
EQUITY | Jul 15, 2026, 09:26 PM UTC
L
URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. p
URGN Urogen receives new U.S. patent allowance expected to provide Protection into July 2044 for zusduri™ and ugn-103 Urogen Pharma - U.S. patent expected to expire in July 2044 - Patent claims cover treatment of recurre
EQUITY | Jul 15, 2026, 12:04 PM UTC
L
Urogen Pharma Insider Sold Shares Worth $400,000, According to a Recent SEC Filing
() -- Mark Schoenberg, Chief Medical Officer, on July 09, 2026, sold 10,000 shares in Urogen Pharma (URGN) for $400,000. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 119,763 ordinary s
REGULATION | Jul 10, 2026, 06:28 PM UTC
L
UroGen Pharma Gets FDA Clearance to Begin Phase 1 Trial of UGN-501
() -- UroGen Pharma (URGN) said Wednesday the US Food and Drug Administration cleared its investigational new drug application for UGN-501, allowing the company to begin a phase 1 trial in patients with non-muscle invasi
REGULATION | Jul 08, 2026, 12:23 PM UTC
L
UroGen Pharma announces FDA clearance for UGN-501 IND application
UroGen Pharma announced that the FDA cleared the company's investigational new drug application, or IND, for UGN-501, an investigational oncolytic virus. The IND clearance enables initiation of a planned Phase 1 clinical
REGULATION | Jul 08, 2026, 12:03 PM UTC